| Name | Agomelatine hydrochloride |
| Description | Agomelatine hydrochloride (S-20098 hydrochloride) is a specific MT1 and MT2 receptor agonist with Ki values of 0.1 nM for CHO-hMT1, 0.06 nM for HEK-hMT1, 0.12 nM for CHO-hMT2, and 0.27 nM for HEK-hMT2, respectively [1]. Additionally, Agomelatine hydrochloride is a selective antagonist of the 5-HT2C receptor with pKi values of 6.4 and 6.2 for native (porcine) and cloned human 5-HT2C receptors, respectively [2]. |
| In vitro | Agomelatine (S 20098) functions as a full agonist for the MT1 and MT2 receptors, exhibiting EC50 values of 1.6±0.4 and 0.10±0.04 nM, respectively, when expressed in CHO or HEK cell membranes. Additionally, Agomelatine interacts with h5-HT2B receptors, displaying a marked preference (6.6). However, it demonstrates low affinity for both native and cloned human 5-HT2A receptors, with values just below 5.0/5.3, and similarly low affinity for 5-HT1A receptors (below 5.0/5.2), while exhibiting negligible affinity for other 5-HT receptors. |
| In vivo | Agomelatine (25, 50, or 75 mg/kg; i.p.) exhibits antioxidant activity in Strychnine (75 mg/kg, i.p.) or Pilocarpine (400 mg/kg, i.p.) induced seizure models in mice, but does not affect oxidative stress parameters in Pentylenetetrazole (PTZ) or Picrotoxin (PTX) induced seizure models compared to controls[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 0.1 mg/mL (insoluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (11.8 mM), Sonication is recommended.
DMSO : 90 mg/mL (321.7 mM), Sonication is recommended.
|
| Keywords | S-20098 Hydrochloride | S20098 Hydrochloride | S 20098 Hydrochloride | MTReceptor | MT2 receptor | MT1 receptor | MT Receptor | Agomelatine Hydrochloride |
| Inhibitors Related | Sucrose | Aceglutamide | Emtricitabine | 3-Hydroxybutyric acid sodium | Levulinic acid | D(+)-Raffinose pentahydrate | D-(+)-Trehalose dihydrate | Glycerol | Thymidine | Sodium 2-hydroxybutanoate | Chitosan oligosaccharide | 3-Indoleacetic acid |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Failed Clinical Trials Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Approved Drug Library | Antidepressant Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max |
United States
